Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
- PMID: 37369081
- PMCID: PMC10852367
- DOI: 10.1200/JCO.22.02887
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Abstract
Purpose: Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings. Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting.
Patients and methods: In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as monotherapy or in combination with Pembro. The primary end point was confirmed objective response rate (cORR) per blinded independent central review. Secondary end points included duration of response (DOR) and safety. There were no formal statistical comparisons between treatment arms.
Results: The cORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV + Pembro (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy; 65.4% and 56.3% of patients who responded to the combination and monotherapy, respectively, maintained a response at 12 months. The most common grade 3 or higher treatment-related adverse events (TRAEs) in patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutropenia (9.2%). EV TRAEs of special interest (any grade) in the combination arm included skin reactions (67.1%) and peripheral neuropathy (60.5%).
Conclusion: EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.
Trial registration: ClinicalTrials.gov NCT03288545.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
Figures
![FIG 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g001.gif)
![FIG 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g003.gif)
![FIG 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g004.gif)
![FIG 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g005.gif)
![FIG 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g006.gif)
![FIG A1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g011.gif)
![FIG A2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g012.gif)
![FIG A3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10852367/bin/jco-41-4107-g013.gif)
Comment in
-
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.J Clin Oncol. 2023 Sep 1;41(25):4084-4086. doi: 10.1200/JCO.23.00987. Epub 2023 Jul 25. J Clin Oncol. 2023. PMID: 37490639 No abstract available.
Similar articles
-
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.Front Oncol. 2024 Apr 22;14:1326715. doi: 10.3389/fonc.2024.1326715. eCollection 2024. Front Oncol. 2024. PMID: 38711854 Free PMC article. Review.
-
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.J Clin Oncol. 2023 Jan 1;41(1):22-31. doi: 10.1200/JCO.22.01643. Epub 2022 Aug 30. J Clin Oncol. 2023. PMID: 36041086 Free PMC article.
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
-
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.J Clin Oncol. 2024 Apr 20;42(12):1403-1414. doi: 10.1200/JCO.23.01547. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215355 Free PMC article. Clinical Trial.
-
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.Urol Oncol. 2022 Oct;40(10):413-423. doi: 10.1016/j.urolonc.2022.07.006. Epub 2022 Aug 13. Urol Oncol. 2022. PMID: 35973928 Review.
Cited by
-
Proteomic analysis of the urothelial cancer landscape.Nat Commun. 2024 May 27;15(1):4513. doi: 10.1038/s41467-024-48096-5. Nat Commun. 2024. PMID: 38802361 Free PMC article.
-
Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.Ther Adv Urol. 2024 May 20;16:17562872241249073. doi: 10.1177/17562872241249073. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 38779496 Free PMC article. Review.
-
How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma.Cancers (Basel). 2024 May 5;16(9):1780. doi: 10.3390/cancers16091780. Cancers (Basel). 2024. PMID: 38730732 Free PMC article. Review.
-
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.Front Oncol. 2024 Apr 22;14:1326715. doi: 10.3389/fonc.2024.1326715. eCollection 2024. Front Oncol. 2024. PMID: 38711854 Free PMC article. Review.
-
Targeted protein degradation: from mechanisms to clinic.Nat Rev Mol Cell Biol. 2024 Apr 29. doi: 10.1038/s41580-024-00729-9. Online ahead of print. Nat Rev Mol Cell Biol. 2024. PMID: 38684868 Review.
References
-
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
-
- Shah MV, McGovern A, Hepp Z. Targeted literature review of the burden of illness in urothelial carcinoma. Value Health. 2018;21:S32–S33.
-
- Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506–513. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical